Baiyu was awarded “Enterprises with the Most Investment Value in Chinese Pharmaceutical Industry 2017” by China National Pharmaceutical Industry Information Center on the National Industrial Information Annual Meeting on 2nd of September. This is Baiyu’s third time of awarding since 2015. The rewarding is based on assessment on the company and product performance. In terms of company performance, the leading role in therapeutic area, the stable revenue, overlap between researched products and marketed products, stable development of the company is highly valued. In terms of products, research innovation, advanced and sustainable pipeline, the maturity of marketed products, potentials of products under research, the future competitiveness of new drug and the present products’ marketing status is remarkably considered. The awarding draws a lot of attractions from the industry and other companies.